• 1
    Socinski MA, Morris DE, Masters GA, Lilenbaum R; American College of Chest Physicians. Chemotherapeutic management of stage IV nonsmall cell lung cancer. Chest. 2003; 123 (suppl 1): 226S-243S.
  • 2
    O'Shaughnessy J. Extending survival with chemotherapy in metastatic breast cancer. Oncologist. 2005; 10(suppl 3): 20-29.
  • 3
    Jemal A, Ward E, Thun M. Declining death rates reflect progress against cancer. PLoS One. 2010; 5: e9584.
  • 4
    Li X, Butts C, Fenton D, King K, Scarfe A, Winget M. Utilization of oncology services and receipt of treatment: a comparison between patients with breast, colon, rectal, or lung cancer. Ann Oncol. 2011; 22: 1902-1909.
  • 5
    Earle CC, Venditti LN, Neumann PJ, et al. Who gets chemotherapy for metastatic lung cancer? Chest. 2000; 117: 1239-1246.
  • 6
    Schiller JH, Harrington D, Belani CP, et al; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med. 2002; 346: 92-98.
  • 7
    Sonpavde G, Watson D, Tourtellott M, et al. Frequency of cisplatin administration in patients presenting with advanced urothelial carcinoma in the community. Clin Oncol. 30, 2012 (suppl 5; abstr 285).
  • 8
    Winchester DP, Stewart AK, Phillips JL, Ward EE. The national cancer data base: past, present, and future. Ann Surg Oncol. 2010; 17: 4-7.
  • 9
    Halpern MT, Ward EM, Pavluck AL, Schrag NM, Bian J, Chen AY. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol. 2008; 9: 222-231.
  • 10
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29.
  • 11
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012: a review of current American Cancer Society guidelines and current issues in cancer screening [published online ahead of print January 19, 2012]. CA Cancer J Clin. doi: 10.3322/caac.20143.
  • 12
    Hurria A, Togawa K, Mohile SG, et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol. 2011; 29: 3457-3465.
  • 13
    Wang S, Wong ML, Hamilton N, Davoren JB, Jahan TM, Walter LC. Impact of age and comorbidity on nonsmall-cell lung cancer treatment in older veterans [published online ahead of print March 26, 2012]. J Clin Oncol.
  • 14
    Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. JAMA. 2002; 287: 2106-2113.
  • 15
    Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001; 91: 178-188.
  • 16
    Schwartz KL, Crossley-May H, Vigneau FD, Brown K, Banerjee M. Race, socioeconomic status and stage at diagnosis for five common malignancies. Cancer Causes Control. 2003; 14: 761-766.
  • 17
    Landrum MB, Keating NL, Lamont EB, et al. Survival of older patients with cancer in the Veterans Health Administration versus fee-for-service Medicare. J Clin Oncol. 2012; 30: 1072-1079.
  • 18
    Chen JY, Diamant A, Pourat N, Kagawa-Singer M. Racial/ethnic disparities in the use of preventive services among the elderly. Am J Prev Med. 2005; 29: 388-395.
  • 19
    Hoffman-Goetz L, Breen NL, Meissner H. The impact of social class on the use of cancer screening within three racial/ethnic groups in the United States. Ethn Dis. 1998; 8: 43-51.